AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 2026 European Academy Of Dermatology And Venereology Congress

AbbVie (NYSE: ABBV) presented late-breaking results from its Phase 3 Viti-Up-1 and Viti-Up-2 trials of RINVOQ (upadacitinib) for non-segmental vitiligo at the 2026 EADV Congress, demonstrating continued facial and total body repigmentation through week 76. Additionally, findings from a phototherapy substudy indicated that patients receiving RINVOQ combined with whole-body NB-UVB phototherapy had numerically higher repigmentation responses compared to those receiving RINVOQ alone.